Matthieu Meryet-Figuiere
Overview
Explore the profile of Matthieu Meryet-Figuiere including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
428
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Wambecke A, Ahmad M, Morice P, Lambert B, Weiswald L, Vernon M, et al.
Mol Oncol
. 2021 Jun;
15(12):3659-3678.
PMID: 34160887
Ovarian cancer (OC) is the leading cause of death in patients with gynecologic cancers. Due to late diagnosis and resistance to chemotherapy, the 5-year survival rate in patients with OC...
12.
Baldi I, De Graaf L, Bouvier G, Gruber A, Loiseau H, Meryet-Figuiere M, et al.
Cancer Causes Control
. 2021 Apr;
32(7):773-782.
PMID: 33876308
Background: The etiology of the central nervous system (CNS) tumors remains largely unknown. The role of pesticide exposure has been suggested by several epidemiological studies, but with no definitive conclusion....
13.
Meryet-Figuiere M, Ali M, Subhash S, Kanduri C
Methods Mol Biol
. 2020 Dec;
2254:239-249.
PMID: 33326079
From high-throughput DNA and RNA sequencing technologies, it is evident that more than two-thirds of the mammalian genome is transcribed and nearly 98% of the transcriptional output in humans constitute...
14.
Busson A, Gac A, Gruson B, Meryet-Figuiere M, Baldi I, Tual S, et al.
Med Sci (Paris)
. 2020 Oct;
36 Hors série n° 1:16-22.
PMID: 33052088
No abstract available.
15.
Vernon M, Lambert B, Meryet-Figuiere M, Brotin E, Weiswald L, Paysant H, et al.
Mol Cancer Ther
. 2020 May;
19(7):1506-1519.
PMID: 32371581
Novel therapeutic strategies are urgently required for the clinical management of chemoresistant ovarian carcinoma, which is the most lethal of the gynecologic malignancies. miRNAs hold promise because they play a...
16.
Vigneron N, Vernon M, Meryet-Figuiere M, Lambert B, Briand M, Louis M, et al.
Clin Chem
. 2020 Feb;
66(2):352-362.
PMID: 32040573
Background: Identifying patients with high-grade serous ovarian cancer (HGSOC) who will respond to treatment remains a clinical challenge. We focused on miR-622, a miRNA involved in the homologous recombination repair...
17.
Wambecke A, Ahmad M, Lambert B, Joly F, Poulain L, Denoyelle C, et al.
Gynecol Oncol
. 2019 Dec;
156(3):726-733.
PMID: 31883617
With 240,000 new cases and 152,000 deaths per year, ovarian cancer is the leading cause of death from gynecologic malignancies. Late diagnosis because of asymptomatic development in early stages and...
18.
Ali M, Akhade V, Thankaswamy Kosalai S, Subhash S, Statello L, Meryet-Figuiere M, et al.
Nat Commun
. 2018 Mar;
9(1):883.
PMID: 29491376
Despite improvement in our understanding of long noncoding RNAs (lncRNAs) role in cancer, efforts to find clinically relevant cancer-associated lncRNAs are still lacking. Here, using nascent RNA capture sequencing, we...
19.
Meryet-Figuiere M, Lecerf C, Varin E, Coll J, Louis M, Dutoit S, et al.
Oncol Rep
. 2017 Aug;
38(4):1949-1958.
PMID: 28791387
Ovarian cancer is the leading cause of death from gynecological malignancies worldwide, and innate or acquired chemoresistance of ovarian cancer cells is the major cause of therapeutic failure. It has...
20.
Mandilaras V, Vernon M, Meryet-Figuiere M, Karakasis K, Lambert B, Poulain L, et al.
Expert Opin Biol Ther
. 2017 Jun;
17(8):927-943.
PMID: 28641048
Ovarian cancer (OC) is the second most common and the most lethal of the gynecological malignancies. Currently, there exists no effective screening tool for OC. MicroRNAs (miRNAs) are endogenous 18-23...